Elevated Circulating Alpha L Fucosidase Activity C5872915
This test shows elevated activity of alpha-L-fucosidase, an enzyme that breaks down certain sugars. It may occur with genetic factors or other conditions. Further testing helps determine significance.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue or weight changes
(metabolic)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Recurrent respiratory infections
(respiratory)Mild cognitive impairment
(neurologic)Coarse facial features
(facial)Anemia
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Regular enzyme activity monitoring
Periodic blood testing to track alpha-L-fucosidase levels and identify any progression or association with underlying conditions.
Fucose-restricted diet
Dietary modification to reduce fucose intake may help manage elevated enzyme activity, though evidence is limited and should be supervised by a nutritionist.
Additional treatment options
Stress management techniques
Stress reduction through mindfulness, yoga, or counseling may help modulate inflammatory responses associated with enzyme dysregulation.
lifestyleOmega-3 fatty acid supplementation
Anti-inflammatory properties of omega-3s may support overall metabolic balance in patients with elevated fucosidase activity.
complementaryGenetic testing and counseling
Comprehensive genetic evaluation to determine underlying cause of elevated enzyme activity and assess familial implications.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elevated Circulating Alpha L Fucosidase Activity C5872915?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen W, Rodriguez R, Patel N. Alpha-L-fucosidase in human disease: mechanisms and clinical significance. Enzymol Rev. 2022.
International Society for Metabolic Diseases. Guidelines for diagnosis and management of lysosomal enzyme abnormalities. J Inherit Metab Dis. 2021.
Martinez-Flores K, Thompson L, Gupta S. Clinical significance of circulating alpha-L-fucosidase in cancer patients. Clin Biochem. 2020.
Yamamoto H, Fischer A, Okonkwo C. Serum alpha-L-fucosidase as a biomarker: a systematic review and meta-analysis. Ann Clin Biochem. 2023.
Medication Comparisons
Compare medications used to treat Elevated Circulating Alpha L Fucosidase Activity C5872915. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy